# GlycoEra AG

> GlycoEra AG is a Swiss-American clinical-stage biotech building a new class of precision medicines that selectively degrade the circulating proteins driving autoimmune disease. Spun out of LimmaTech Biologics in 2021 and powered by a proprietary glycoengineering platform, the company designs bifunctional biologics (G-LyTACs) that pull pathogenic autoantibodies out of the bloodstream with speed and depth - without the broad immune suppression of existing therapies. Its lead program, GE8820, targets pathogenic IgG4 autoantibodies. Backed by $179M across Series A and an oversubscribed $130M Series B, GlycoEra operates from Wädenswil, Switzerland and Newton, Massachusetts.

- **Founded:** 2020
- **Headquarters:** Wädenswil, Switzerland (with offices in Newton, Massachusetts, USA)
- **Founders:** Amir Faridmoayer (Co-founder, Chief Scientific Officer), Veronica Gambillara Fonck (Co-founder, founding CEO), Dominique N. Sirena (Co-founder, VP Operations & Technology)
- **Team size:** ~31 employees
- **Products:** Glycoengineering / G-LyTAC platform, GE8820 (lead program), Second pipeline program
- **Notable:** Spun out of LimmaTech Biologics and raised CHF 45M / US$49M Series A in 2021, Closed an oversubscribed US$130M Series B in May 2025, bringing total funding to roughly $179M, Attracted top-tier investors including Novo Holdings, Sofinnova, Roche and Bristol Myers Squibb

## Products & services

- **Glycoengineering / G-LyTAC platform** — A proprietary platform that designs bifunctional biologics combining a target-binding domain with an engineered glycan that engages receptors to traffic the bound protein to the lysosome for degradation. Applicable to any disease driven by circulating extracellular proteins.
- **GE8820 (lead program)** — An extracellular protein degrader designed to clear pathogenic IgG4 autoantibodies with speed, depth, and selectivity not attainable by current modalities, and without immunosuppression. Targets IgG4-driven diseases such as pemphigus, MuSK myasthenia gravis, primary membranous nephropathy, and autoimmune encephalitis.
- **Second pipeline program** — An additional precision extracellular degrader in immunology that the company aims to advance toward the clinic, with a potential trial application in 2026.

## Achievements

- Spun out of LimmaTech Biologics and raised CHF 45M / US$49M Series A in 2021
- Closed an oversubscribed US$130M Series B in May 2025, bringing total funding to roughly $179M
- Attracted top-tier investors including Novo Holdings, Sofinnova, Roche and Bristol Myers Squibb
- Advanced lead degrader GE8820 toward clinical development
- Built dual operations across Wädenswil, Switzerland and Newton, Massachusetts

## Latest updates

- **2025-05** — Closed an oversubscribed $130M Series B led by Novo Holdings to advance GE8820 through clinical data and bring a second program toward the clinic.
- **2024-05** — Ganesh V. Kaundinya appointed President and CEO; new brand identity and website launched.
- **2021-11** — Raised CHF 45M (US$49M) Series A to build out the glycoengineering platform and pipeline.

## Links

- Website: https://www.glycoera.com
- LinkedIn: https://www.linkedin.com/company/glycoera-ag
- Twitter/X: https://twitter.com/glycoera

---

Profile page: https://yespress.io/glycoera-ag
Published by YesPress — https://yespress.io
Last updated: 2026-06-07